I would suggest that those with questions who are not going to the AGM compile a short list and send them to Paul Moon ASAP and perhaps he or another IR person would read them into the Q&A session. I don't think that would be an unreasonable request, especially this year.  

If I go I had planned to ask about the "clinic ready" pipeline they have been talking about for years but I'm not sure if I will make it. I'm not sure anyone will ever get a straight answer as far as data release for secondary endpoints and detailed data.